Antimalarials in systemic lupus erythematosus: benefits beyond disease activity
Future Rheumatology · 2006-04 · 1 (2) · 225-233
DOI: 10.2217/17460816.1.2.225 ↗Kurz gefasst
Fachartikel in der Zeitschrift Future Rheumatology, 2006-04. Verfasst von Rosa M Andrade und 1 weiteren Autor:innen. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 56 Literaturangaben.
Abstract (Originalsprache)
Antimalarials, particularly hydroxychloroquine, have proven beneficial effects beyond the control of disease activity among systemic lupus erythematosus patients. Indeed, recent data support the notion that prolonged treatment with hydroxychloroquine prevents damage accrual. Furthermore, this protective effect may expand to increased survival. Although toxicity remains a concern, it is rare and should not prevent practitioners from recommending hydroxychloroquine to all lupus patients, including children and pregnant women. Adequate ophthalmological monitoring and dosing should take place.
Zitieren
APA
Andrade, R. M., & Alarcón, G. S. (2006). Antimalarials in systemic lupus erythematosus: benefits beyond disease activity. Future Rheumatology, 1(2), 225-233. https://doi.org/10.2217/17460816.1.2.225
Vancouver
Andrade RM, Alarcón GS. Antimalarials in systemic lupus erythematosus: benefits beyond disease activity. Future Rheumatology. 2006;1(2):225-233. doi:10.2217/17460816.1.2.225
BibTeX
@article{Andrade2006,
author = {Andrade, Rosa M and Alarcón, Graciela S},
title = {Antimalarials in systemic lupus erythematosus: benefits beyond disease activity},
journal = {Future Rheumatology},
year = {2006},
volume = {1},
number = {2},
pages = {225--233},
doi = {10.2217/17460816.1.2.225}
}
EUVIMED